. Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer's Disease. CNS Drugs. 2018 Dec;32(12):1085-1090. PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.